Initial data from phase II trial of Ixempra indicates potential for improved clinical benet inDRP-selected metastatic breast cancer patients

Researchers pre-screened mBC patients using Allarity’s DRP-Ixempra CDx, a complex transcriptomic signature comprising multiple mRNA biomarkers of drug response/resistance. Patients were assigned a DRP score, and those with scores above 67% were selected for treatment with Ixempra. Of the 36 patients screened with the DRP -Ixempra CDx, investigators identified five DRP positive patients. Among the evaluable patients assessed up to the data evaluation cut-off, there were promising signs of clinical benefit in four out of four evaluable cases: i. One partial responder (PR) (tumor shrinkage of 66%). ii. One partial responder (PR) (tumor shrinkage of 59%).iii One patient experienced 24 weeks of stable disease. iv. One patient experienced 19 weeks of stable disease.

“ We are enthusiastic about these promising very early trial results since the observed clinical benefit rate exceeds what has been historically observed for Ixemptra treatment without the DRP -Ixempra CDx patient selection. While still early, these data suggest that the use of the DRP -Ixempra CDx for patient selection and treatment may help identify mBC patients most able to benefit from this course of treatment.

Accordingly, the DRP -Ixempra CDx , if approved, may provide clinicians with an important diagnostic to guide patient treatment in this hard-to-treat population, " said Marie Foegh, M.D., Chief Medical Officer of Allarity.

The study is in a very early stage of an ongoing open-label, single-arm trial, at multiple sites in Europe, evaluating the anti-tumor effect of Ixampra in patients with locally recurrent or metastatic breast cancer after previous chemotherapies, including a taxane and an anthracycline. The included patients received a maximum of three prior lines of chemotherapies in the metastatic setting. Allarity recently amended the clinical trial protocol, lowering the DRP cut-off score in order to include more likely responder patients while still excluding those unlikely to respond to the drug. The ultimate objective is to further refine the DRP- Ixempra CDx criteria and broaden the enrollment of mBC patients who may substantially benefit from this treatment. The Company anticipates an additional interim data readout before the end of this year.

The DRP-Ixempra CDx is a transcriptomic signature comprising 191 mRNA biomarkers that are collectively predictive of tumor sensitivity or resistance to Ixempra Using the DRP- CDx to select likely responder patients while excluding likely resistant ones, Allarity aims to improve the benefit-risk ratio of Ixempra in metastatic or locally advanced breast cancer. The FDA-approved Ixempra label currently indicates a monotherapy efficacy with an objective response rate (ORR) of 12.4% and a clinical benefit rate (CBR) of 24.8% in metastatic or locally advanced breast cancer. However, the initial data from the ongoing DRP-guided Phase II study of Ixempra suggest that the DRP-Ixempra CDx may identify a subset of patients who potentially have an improved ORR and CBR as compared to monotherapy efficacy indicated by the FDA-approved label for the drug.

The DRP- Ixempra CDx is a clinical stage companion diagnostic candidate and has not yet been approved by the FDA or the EMEA. Early trial results are insufficient to show statistical significance and may not be a reliable indicator of subsequent trial results based on a larger patient population.

Ixempra was originally developed by Bristol Myers Squibb and is approved for metastatic breast cancer patients in the U.S., where it is marketed by R-PHARM U.S., LLC.

Allarity has the exclusive option rights for the development and commercialization of Ixempra in Europe.

Allarity’s Chief Executive Ocer, James G. Cullem, further stated, “We are encouraged by these promising, early clinical data suggesting that mBC patients selected for treatment with Ixempra using our DRP companion diagnostic candidate for the drug may have substantially improved clinical benefit versus unselected patients. Allarity looks forward to fully enrolling and completing our ongoing Phase II trial for Ixempra, and remains enthusiastic about advancing this program towards market approval in Europe.